Skip to main content
SpringerLink
Log in

The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians

  • Original Research
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

The MDR1 gene encodes for P-glycoprotein (P-gp), which is an efflux transporter at the cell membrane. The P-gp has wide substrate specificity for multiple medications including the lipid lowering drug, atorvastatin. In this study, we investigated the possible association between three common MDR1 gene polymorphisms (G2677T, C3435T, and C1236T), and the lipid lowering effect of atorvastatin among Jordanians. Lipid and lipoproteins were measured in blood samples collected from patients (n = 201) at baseline and during atorvastatin treatment. MDR1 polymorphisms were genotyped using polymerase chain reaction–restriction fragment length polymorphism. Both the TT genotype of G2677T and the TT genotype of the C3435T polymorphisms were associated with lower levels of low-density lipoproteins after atorvastatin treatment. However, the effects of atorvastatin on the levels of total cholesterol, triglycerides, and high-density lipoprotein, were not correlated with any of the genotypes in both polymorphisms. Finally, the C1236T polymorphism was not associated with the lipid lowering effect of atorvastatin. In conclusion, the MDR1 gene polymorphisms G2677T, and C3435T, but not C1236T were associated with the lipid lowering effect of atorvastatin among Jordanians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Allabi AC, Gala JL, Horsmans Y (2005) CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 15:779–786

    Article  CAS  Google Scholar 

  • Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P (2004) CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75:422–433. doi:10.1016/j.clpt.2004.01.009

    Article  CAS  Google Scholar 

  • Bellusci CP, Rocco CA, Aulicino PC, Mecikovsky D, Bologna R, Sen L, Mangano A (2010) MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. AIDS 24:833–840. doi:10.1097/QAD.0b013e328336abfc

    Article  CAS  Google Scholar 

  • Bodor M, Kelly EJ, Ho RJ (2005) Characterization of the human MDR1 gene. Aaps J 7:E1–E5

    Article  Google Scholar 

  • Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261–283. doi:10.1007/978-3-642-14541-4_6

    Article  CAS  Google Scholar 

  • Chelule PK, Gordon M, Palanee T, Page T, Mosam A, Coovadia HM, Cassol S (2003) MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 74:195–196

    Article  CAS  Google Scholar 

  • Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P (2007) Effects of azithromycin on the expression of ATP binding cassette transporters in epithelial cells from the airways of cystic fibrosis patients. J Chemother 19:643–649

    Article  CAS  Google Scholar 

  • DeGorter MK, Xia CQ, Yang JJ, Kim RB (2012) Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–273. doi:10.1146/annurev-pharmtox-010611-134529

    Article  CAS  Google Scholar 

  • Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, Demicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA (2012) Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res 53:1000–1011. doi:10.1194/jlr.P021113

    Article  CAS  Google Scholar 

  • Dong HJ, Miao KR, Qiao C, Zhuang Y, Shen WY, Hong M, Fan L, Liu P, Xu W, Li JY (2011) Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. Leuk Lymphoma 52:1003–1009. doi:10.3109/10428194.2011.557454

    Article  CAS  Google Scholar 

  • Foger B (2011) Lipid lowering therapy in type 2 diabetes. Wien Med Wochenschr 161:289–296. doi:10.1007/s10354-011-0908-4

    Article  Google Scholar 

  • Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59:303–312. doi:10.1007/s00228-003-0606-2

    Article  CAS  Google Scholar 

  • Gelskey DE, Young TK, MacDonald SM (1994) Screening with total cholesterol: determining sensitivity and specificity of the National Cholesterol Education Program’s guidelines from a population survey. J Clin Epidemiol 47:547–553

    Article  CAS  Google Scholar 

  • Goldstein DB (2005) The genetics of human drug response. Philos Trans R Soc Lond B Biol Sci 360:1571–1572. doi:10.1098/rstb.2005.1686

    Article  CAS  Google Scholar 

  • Goreva OB, Grishanova AY, Domnikova NP, Mukhin OV, Lyakhovich VV (2004) MDR1 Gene C1236T and C6 + 139T polymorphisms in the Russian population: associations with predisposition to lymphoproliferative diseases and drug resistance. Bull Exp Biol Med 138:404–406

    Article  CAS  Google Scholar 

  • Haslam IS, Jones K, Coleman T, Simmons NL (2008) Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol 76:850–861

    Article  CAS  Google Scholar 

  • Hattori H, Suminoe A, Wada M, Koga Y, Kohno K, Okamura J, Hara T, Matsuzaki A (2007) Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res 31:1633–1640

    Article  CAS  Google Scholar 

  • Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

    Article  CAS  Google Scholar 

  • Jiang XY, Zhang Q, Chen P, Li SY, Zhang NN, Chen XD, Wang GC, Wang HB, Zhuang MQ, Lu M (2012) CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther 37:719–723

    Google Scholar 

  • Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2004) Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93:1046–1050

    Article  CAS  Google Scholar 

  • Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T (2008) ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32:398–404. doi:10.1016/j.pnpbp.2007.09.003

    Article  CAS  Google Scholar 

  • Khabour OF, Alzoubi KH, Al-azzam SI, Mhaidat NM (2012) Identification and distribution of MDR1 single nucleotide polymorphisms in Jordanian population: detection of a novel variant. Gen Mol Res 12:801–808

    Google Scholar 

  • Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199. doi:10.1067/mcp.2001.117412

    Article  CAS  Google Scholar 

  • Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K (2006) MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21:126–132

    Article  CAS  Google Scholar 

  • Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y (2008) Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 18:861–868

    Article  CAS  Google Scholar 

  • Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141–1160

    Article  Google Scholar 

  • Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302–3311

    Article  CAS  Google Scholar 

  • Li YP, Zhang LR, Jia M, Hu XJ (2011) CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol 51:181–188. doi:10.1177/0091270010370589

    Article  CAS  Google Scholar 

  • Maeda K, Sugiyama Y (2008) Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23:223–235

    Article  CAS  Google Scholar 

  • Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS (2009) Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 29:1310–1315. doi:10.1161/ATVBAHA.109.188474

    Article  CAS  Google Scholar 

  • Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R (2011) Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep 63:808–814

    Article  CAS  Google Scholar 

  • Munshi A (2012) Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke. Hum Genet 131:1775–1781

    Google Scholar 

  • Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD (2005) High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 38:1389–1397

    Article  CAS  Google Scholar 

  • Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA (2012) Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta 413:495–501. doi:10.1016/j.cca.2011.11.003

    Article  CAS  Google Scholar 

  • Rosenberg MF, Callaghan R, Ford RC, Higgins CF (1997) Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272:10685–10694

    Article  CAS  Google Scholar 

  • Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383–384

    Article  CAS  Google Scholar 

  • Wang D, Sadee W (2006) Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). Aaps J 8:E515–E520

    Article  CAS  Google Scholar 

  • Woodahl EL, Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11–19

    Article  CAS  Google Scholar 

  • Zhang Y, Jiang XH, Hu YQ, Li ZR, Su L, Wang ZG, Ma G (2008) MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br J Clin Pharmacol 66:247–254. doi:10.1111/j.1365-2125.2008.03189.x

    Article  CAS  Google Scholar 

  • Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9:738–784

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant to KA from the Scientific Research funds, Amman, Jordan.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan

    Karem H. Alzoubi, Sayer I. Al-azzam, Fadia Mayyas & Nizar M. Mhaidat

  2. Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, 22110, Jordan

    Omar F. Khabour

Authors
  1. Karem H. Alzoubi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omar F. Khabour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayer I. Al-azzam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fadia Mayyas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nizar M. Mhaidat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karem H. Alzoubi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alzoubi, K.H., Khabour, O.F., Al-azzam, S.I. et al. The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians. Cytotechnology 67, 267–274 (2015). https://doi.org/10.1007/s10616-013-9682-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-013-9682-z

Keywords

Search

Navigation